A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies

Annals of Oncology

Volumn 11, Issue 1, 2000, Pages 73-79

  Delord, J P ^a   Raymond, E ^a   Chaouche, M ^a   Ruffie, P ^a   Ducreux, M ^a   Faivre, S ^a   Boige, V ^a   Le Chevalier, T ^a   Rixe, O ^a   Baudin, E ^a   Pautier, P ^a   Rodier, J M ^a   Chouaki, N ^a   Escudier, B ^a   Kayitalire, L ^b   Armand, J P ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Eli Lilly Company   (France)

Author keywords

Gemcitabine; Pancreatic cancer; Phase I; Vinorelbine

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE; NAVELBINE;

ADULT; AGED; ARTICLE; CANCER; CLINICAL ARTICLE; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; MALE; NEUTROPENIA; PATIENT SELECTION; PRIORITY JOURNAL;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS; PLATELET COUNT; VINBLASTINE;

EID: 17144444809     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008352227275     Document Type: Article

References (28)

1. Huang P, Chubb S, Hertel LW et al. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51: 6110-7.
2. Hertel LW, Boder GB, Kroin JS et al. Evaluation of the antitumor activity of gemcitahine (2′,2′-difluro-2′-deoxycitidine). Cancer Res 1990; 50: 4417-22.
3. Lund B, Kristjansen PEG, Hansen HH. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 1993; 19: 45-55.
4. Storniolo AM, Allerheiligen SRB, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 1997: 24 (2, Suppl 7): 2-7.
5. Abbruzzese JL, Grunewald R, Weeks EA et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-8.
6. Fossella FK, Lippman SM, Shin DM et al. Maximum-tolerated dose defined for single-agent gemcitabine: A phase I dose-escalation study in chemotherapy-naive patients with advanced nonsmall-cell lung cancer. J Clin Oncol 1997; 15: 310-6.
7. HH Hansen, JB Serensen. Efficacy of single-agent gemcitabine in advanced non-small-cell lung cancer: A review. Semin Oncol 1997: 24 (2, Suppl 7): 38-41.
8. Abratt RP. Gemcitabine hydrochloride: Combination of activity and tolerability (Summary). Anticancer Drugs 1995; 6: 63-4.
9. Cvitkovic E, Izzo J. The current and future place of vinorelbine in cancer therapy. Drugs 1992; 44: 36-45.
10. Fumoleau P, Delgado FM, Delozier T et al. Phase II trial of weekly intraveinous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11: 1245-52.
11. Depierre A, Lemarie E, Dabouis G et al. A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 1991; 14: 115-9.
12. Conroy T, Etienne PL, Adenis A et al. Vinorelbine (navelbine): A promising drug in metastalic epidermoid esophageal carcinoma. Proc Am Soc Clin Oncol 1993; 11: 553 (Abstr).
13. Ruiz van Haperen VWT, Veerman G, Boven V et al. Schedule dependence of sensitivity to 2′,2′-difluorodcoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell line and solid tumor. Biochem Pharmacol 1994; 48: 1327-49.
14. Zhou XJ, Rhamani R. Preclinical and clinical pharmacology of vinca alkaloids. Drugs 1992; 44: 1-16.
15. Ruiz van Haperen VWT, Veerman G, Erikson S et al. Development and molecular characterization of a 2′,2′-ditluorodeoxycytidine-resistant variant of the human ovarian cell line A2780. Cancer Res 1994; 54: 4138-43.
16. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: WHO 1979.
17. Abratt RP, Bezwoda WR, Falkson G et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 1994; 12: 1535-40.
18. Anderson H, Lund B, Bach F et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1994; 12: 1821-6.
19. Gatzeimer U, Shepherd FA, Le Chevalier T et al. Activity of gemcitabine in patients with non-small-cell lung cancer: A multicentre, extended phase II studies. Eur J Cancer 1996; 32A: 243-8.
20. Marty M, Extra JM, Dieras V et al. A review of the antitumor activity of vinorelbine in breast cancer. Drugs 1992; 44: 29-35.
21. Guchelaar HJ, Richel DJ, van Knapen A. Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev 1996; 22: 15-31.
22. Krajnik G, Wein W, Griel R et al. Vinorelbine-Gemcitabine in advanced non-small-cell lung cancer (NSCLC): A phase I trial. Eur J Cancer 1998; 34: 1977-80.
23. Sorensen JB, Osterlind K, Hansen HH. Vinca alkaloids in the treatment of non-small-cell lung cancer. Cancer Treat Rev 1987; 14: 29-51.
24. Carmichael J, Fink U, Russel RCG et al. Phase II study of genicitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 101-5.
25. Burris H, Stornolio AM. Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997; 33 (Suppl 1): S18-22.
26. Ahlgren JD. Chemotherapy for pancreatic carcinoma. Cancer 1996; 78 (3): 654-63.
27. Cella DK, Tulsky DS. Measuring quality of life today: Methodological aspects. Oncology 1990; 4: 29-42.
28. Krajnik G, Wein W, Greil R et al. Vinorelbine gemcitabine in advanced non-small-cell lung cancer (NSCLC): A phase I trial. Eur J Cancer 1998; 34 (12): 1977-80.